Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. - Wikidata - awgldk - TriplyDB

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

http://www.wikidata.org/entity/Q42293558

about

Inflammatory status in human hepatic cirrhosis Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy Management of cirrhotic ascites Proposed benefits of albumin from the ALBIOS trial: a dose of insane belief Ascites bacterial burden and immune cell profile are associated with poor clinical outcomes in the absence of overt infection.Re-re-treatment of hepatitis C virus: Eight patients who relapsed twice after direct-acting-antiviral drugs ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial.Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.SCISSOR-Spinal Cord Injury Study on Small molecule-derived Rho inhibition: a clinical study protocol.Novel prevention strategies for bacterial infections in cirrhosis.Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats.Sorting out cirrhosis: mechanisms of non-response to hepatitis C therapy.Immunotherapy in the treatment and prevention of infection in acute-on-chronic liver failure.Albumin in chronic liver disease: structure, functions and therapeutic implications.Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy.Acute-on-chronic liver failure: terminology, mechanisms and management.The Acute-on-Chronic Liver Failure Syndrome, or When the Innate Immune System Goes Astray.Acute-on-chronic liver failure: an update.Polymorphisms in the IL-1 gene cluster influence systemic inflammation in patients at risk for acute-on-chronic liver failure.Albumin gains immune boosting credibility Albumin Prevents Infections in Patients with Chronic Liver Failure in a Single-arm Feasibility Trial.Albumin Counteracts Immune-suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease.The anti-inflammatory effects of PGE2 on human lung macrophages are mediated by the EP4 receptor.Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase.Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences Inflammatory Resolution Triggers a Prolonged Phase of Immune Suppression through COX-1/mPGES-1-Derived Prostaglandin E2.Prevalence and outcomes of pancreatic cystic neoplasms in liver transplant recipients.High prevalence of hepatitis B-antibody loss and a case report of de novo hepatitis B virus infection in a child after living-donor liver transplantation.High prevalence of hepatitis B-antibody loss and a case report of de novo hepatitis B virus infection in a child after living-donor liver transplantation.Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients.The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer.Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis.Effectiveness of pneumococcal and influenza vaccines to prevent serious health complications in adults with chronic liver disease: a protocol for a systematic review.Systemic Inflammation and Acute-on-Chronic Liver Failure: Too Much, Not Enough ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial Immunodysfunction in Acute-on-Chronic Liver Failure Gut-Liver Axis Links Portal Hypertension to Acute-on-Chronic Liver Failure

P2860

Q26778040-F1FEB308-4824-459E-B5C2-7B252CB027B5 Q27684895-C2AD2A8F-BE3A-41D5-AA9F-7A9F12DD6868 Q34475601-29B0C024-3F75-4B00-A690-81CE4E06B12D Q35092191-9BF66E34-9F5A-4FC9-A938-1F425479A61C Q35189328-CED3813D-4EAF-4DED-9F4D-90BC65F920F8 Q36290416-EF1D344F-1E89-4CE0-83EA-C9F055AF74D9 Q36527179-EA96BE53-37C4-43E7-A03C-6C6EEA08EF1F Q37079141-7D4355D8-4A36-4F31-AD47-18EDD1936324 Q37133751-B2D52BDA-0F58-4EB9-919F-AA44A0CC4524 Q37183463-FE4A48D0-C365-4651-A8CB-D062C4A19ABE Q37262768-C885ED16-7056-4637-AD90-81152B3B6A09 Q38458110-BA64E615-C34E-450E-AEBC-FB6563149CFA Q38524991-1EDBEC97-3AA1-42E1-BED3-8FE74B0DD88A Q38595462-5711EF5C-6C05-40AC-B1AF-D9406901A50A Q38703524-5E8D5224-E6C3-41B6-AD3F-3506F3AEB77F Q38720387-CC9FD69E-F424-4A2B-883D-F8F62777B0E1 Q38999160-EEE35E74-37B3-48BF-8E1B-34E28C8CB17B Q39039989-3D74BA69-5529-4069-871C-9E25283B3196 Q39254763-4DE349A5-0DD5-463A-82C9-9A7988F33C1D Q39642710-18D8FDFE-E60B-406B-ADF6-781078E9F3DF Q40045308-D2EE24D9-E7F4-47D4-9020-3480CB7EF086 Q40072046-E7866F17-A0F4-4EB2-AAB8-E0C90427BCDF Q40599018-5984D23C-A200-4F40-B934-F485B9011A5B Q40798354-07A77F20-A908-42DF-8D7E-4D8121984E01 Q41201824-68D05711-2765-4F70-A130-73ED6D80F8F2 Q42376227-8BCFAADD-FB8F-4FEE-B775-8BF3DBEAF225 Q49429125-AEACE24A-8CA6-4ABE-A1E0-C72116437F7F Q49741477-A55F5A70-0AE6-408C-A140-F401C508A5F9 Q49885440-C69D38AD-A5DD-4355-9819-92272D75C081 Q50010598-B2C85AF4-1418-4ABC-9435-18086ECB3334 Q50350640-E1B696F0-EA1C-449A-A99D-7FAFA4F389E6 Q50472049-FD62EBC1-6B90-43FB-A4A3-66C496F19F37 Q54254456-EC66E2EB-566E-4158-93DB-0A3DC6513B2E Q56924975-D7CA63D5-9FA4-4986-8E19-3AA367DF27ED Q57806275-D439FC73-5D06-4AA6-8109-7E9542ABCB19 Q57824681-A8534CEA-5B33-41BE-ACD1-3C91D50F12E2 Q57824683-3CCE3B25-C015-49B9-88AF-1AAF01254A6C

P2860

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

http://www.wikidata.org/entity/Q42293558

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@en

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@nl

type

label

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@en

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@nl

prefLabel

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@en

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@nl

P1433

Q42293558-51EF9938-414E-4417-AAFE-6110C3CFB439

P1476

Q42293558-0AFDFAEC-01A2-4E0E-B7C0-E652FC82B7DA

P2093

Q42293558-09ED3F9D-F586-4E69-AFE3-D53DA306F535

Q42293558-0D415726-71E4-41FC-9EF3-07E9BC332FF4

Q42293558-0E5C3C20-92D2-402B-9D5F-43D197ACE564

Q42293558-213998C1-4B81-485F-904C-6B63227B60B4

Q42293558-34E649E2-5700-419A-A965-792A567856D4

Q42293558-59B4654C-93C6-4740-ADD8-7A76CD8C952E

Q42293558-6CEBB066-CA9C-4456-BF6F-4E911B5D2CE1

Q42293558-7F3951D6-680C-40DE-9F24-55D005557D26

Q42293558-AB68A88A-64AA-4578-8702-27478E4192CB

Q42293558-D5210D5A-2C0B-4291-BA71-8754FB8C9CE1

P2860

Q42293558-01773A6F-E585-4095-A5E0-260C5D3250FB

Q42293558-104DE7F1-3842-4077-B14D-125F7C93935C

Q42293558-1C78F030-F1C3-45D6-9206-D1A4AE8FF986

Q42293558-24110E8F-EBCF-419E-8992-71654F4203AE

Q42293558-25569EB1-BD0D-4283-AF0A-238A95729B53

Q42293558-26A20C05-D911-49C7-A8B2-E1F210124B51

Q42293558-294237DC-73BA-43ED-BA7D-8687A973DA5B

Q42293558-3FC5E004-C9EB-4841-9972-08B8012A6702

Q42293558-44F7D54A-5B00-46C7-9308-2FBF778B08F7

Q42293558-45802F00-3B9C-409D-8361-51EA1FD81177

P2888

Q42293558-AB79E7B0-115E-490B-AD76-89A6B50A6EB0

P304

Q42293558-0B5613FA-087D-47B6-828A-2C7952C7882F

P31

Q42293558-32FF095E-E8F4-405C-802E-F27738F9AF32

P356

Q42293558-751A903B-AEF3-4DC7-9DA1-E5AB6FAD33EE

P407

Q42293558-9773107D-EE4E-4960-AEAF-C6EC0E05E2A5

P433

Q42293558-1B5195AB-D8ED-4FCF-AA99-6A8E18596639

P478

Q42293558-2B50C92F-5357-4112-B786-65E20DF62D0B

P50

Q42293558-2E9926BD-BCFE-4F8F-9C84-0A98B7315647

Q42293558-73A2C789-89AC-417B-93E9-BC17DB14D3B8

Q42293558-D923849B-9944-42E1-A265-5CC200279C42

P577

Q42293558-CE02FEDB-C2CF-4C4B-8AD5-624493E8D849

P6179

Q42293558-CA65D591-B9A3-42CA-802D-1A27200DC9C4

P698

Q42293558-D3E18264-1BAB-48C4-9545-36BC906A607D

P921

Q42293558-2B43867F-C5C2-4BC6-B01B-EA9AABDE5E40

P932

Q42293558-FE659A73-A0FF-4181-B93D-6C485152164F

P356

P1433

Nature Medicine

P1476

Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

@en

P2093

Alastair J O'Brien

http://www.w3.org/2001/XMLSchema#string

Alison Winstanley

http://www.w3.org/2001/XMLSchema#string

Effie Karra

http://www.w3.org/2001/XMLSchema#string

Gavin Sewell

http://www.w3.org/2001/XMLSchema#string

Grace Auld

http://www.w3.org/2001/XMLSchema#string

Joan Cordoba

http://www.w3.org/2001/XMLSchema#string

Justine Newson

http://www.w3.org/2001/XMLSchema#string

Karen A Massey

http://www.w3.org/2001/XMLSchema#string

Rita Garcia-Martinez

http://www.w3.org/2001/XMLSchema#string

Sarah James

http://www.w3.org/2001/XMLSchema#string

P2860

Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding

Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding

Regulation of immune responses by prostaglandin E2

Bacterial infections in liver cirrhosis.

Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis.

Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial.

Impaired monocyte function in liver cirrhosis

Prostaglandin E2 and the pathogenesis of pulmonary fibrosis.

Regulation of alveolar macrophage p40phox: hierarchy of activating kinases and their inhibition by PGE2

Prostaglandin E2 suppresses bacterial killing in alveolar macrophages by inhibiting NADPH oxidase

P2888

P304

518-523

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.3516

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

James N. Fullerton

P577

2014-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1047038204

http://www.w3.org/2001/XMLSchema#string

P698

24728410

http://www.w3.org/2001/XMLSchema#string

P921

immunosuppression

P932

5369639

http://www.w3.org/2001/XMLSchema#string